首页> 外文OA文献 >Combination chemotherapy of human renal cell carcinoma in athymic nude mice with human lymphoblastoid interferon (HLBI) and UFT, 5-Fu
【2h】

Combination chemotherapy of human renal cell carcinoma in athymic nude mice with human lymphoblastoid interferon (HLBI) and UFT, 5-Fu

机译:人淋巴母细胞干扰素(HLBI)和UFT,5-Fu对无胸腺裸鼠的人肾细胞癌联合化疗

摘要

The effectiveness of interferon alpha (HLBI) for nude mouse transplantable human renal cell carcinoma 72nd general meeting, in combination with UFT and 5-Fu, was examined using, 1 x 10(7) IU/kg, 2 x 10(7) IU/kg HLBI; 25 mg/kg 5-Fu; and 10 mg/kg, 20 mg/kg UFT, administered for 10 consecutive days. The ratio of relative mean tumor weight of treated group to control group was under 42% for the combination of 25 mg/kg (I.P.) 5-Fu, 20 mg/kg UFT, and HLBI and the effect was particularly clear for the combination with 2 x 10(7) IU/kg which indicated a grade IIA histologic classification. In comparison with the control groups only UFT (20 mg/kg) and HLBI (2 x 10(7) IU/kg) showed significant inhibition when administered alone. Although none of the drugs had an inhibitory effect when administered alone, in combined use they showed a strong antitumor effect which was more than synergistic. Orally administered 5-Fu showed a statistically significant difference only in the combination with 2 x 10(7) IU/kg HLBI. Furthermore, the concentration of 5-Fu in the tumor tissue was not affected by the route of administration or drug combination, whereas that in the serum was below the limit of detection in the intraperitoneally administered cases, 0.0096 +/- 0.0079 microgram/ml, lower than the value for orally administered cases. The 5-Fu concentration was 0.026 +/- 0.012 microgram/ml for orally administered UFT which was significantly higher than the value obtained for orally administered 5-Fu. Thus, combination therapy of HLBI and UFT for renal cell carcinoma is expected to be clinically useful.
机译:用1 x 10(7)IU / kg,2 x 10(7)IU检查了干扰素α(HLBI)与裸鼠移植和5-Fu联合使用对第72届全裸小鼠可移植性人肾细胞癌的有效性/ kg HLBI; 25 mg / kg 5-富;连续10天服用10 mg / kg,20 mg / kg UFT。对于25 mg / kg(IP)5-Fu,20 mg / kg UFT和HLBI的组合,治疗组与对照组的相对平均肿瘤重量之比低于42%,并且与2 x 10(7)IU / kg,表示IIA级组织学分类。与对照组相比,单独给药时仅UFT(20 mg / kg)和HLBI(2 x 10(7)IU / kg)表现出明显的抑制作用。尽管单独使用这些药物都没有抑制作用,但在联合使用时,它们显示出强大的抗肿瘤作用,远不止于协同作用。口服5-Fu仅在与2 x 10(7)IU / kg HLBI组合时显示统计学上的显着差异。此外,在肿瘤组织中5-Fu的浓度不受给药途径或药物组合的影响,而在腹膜内给药的情况下,血清中的5-Fu浓度低于检测限,0.0096 +/- 0.0079微克/毫升,低于口服药物的价值。口服UFT的5-Fu浓度为0.026 +/- 0.012微克/毫升,明显高于口服5-Fu的浓度。因此,预期HLBI和UFT联合治疗肾细胞癌在临床上是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号